Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-12-23FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc.
-
FDA approval · 2016-12-23FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for SYNJARDY, the fixed-dose combination of empagliflozin and metformin hydrochloride, submitted by …
-
FDA approval · 2016-12-23FDA Approved: JENTADUETO XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for JENTADUETO XR (linagliptin and metformin hydrochloride) submitted by Boehringer Ingelheim Pharma…
-
FDA approval · 2016-12-23FDA Approved: SYNJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Synjardy XR, a fixed-dose combination of empagliflozin and metformin hydrochloride, from Boe…
-
CLINICAL_TRIALS trial_result · 2016-12-22Clinical Trial Update: Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes [Phase 4]
Phase 4 trial evaluates the efficacy and safety of insulin aspart in subjects with type 1 or type 2 diabetes.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-12-21Clinical Trial Update: GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS) [Phase 3]
Phase 3 trial of lixisenatide as monotherapy for type 2 diabetes (GETGOAL-MONO Japan LTS) has completed. The results were posted in December…
-
CLINICAL_TRIALS research · 2016-12-21Clinical Trial Update: Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients [Phase 4]
Phase 4 clinical trial update evaluating the effects of acarbose and vildagliptin on visceral fat distribution in newly diagnosed type 2 dia…
-
FDA label_change · 2016-12-20FDA Approved: TRADJENTA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for Tradjenta (linagliptin) from Boehringer Ingelheim Pharmaceuticals to update the product labeling…
-
CLINICAL_TRIALS trial_result · 2016-12-19Clinical Trial Update: Heart Rate Variability and Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients
Clinical trial NCT02996539 assessing heart rate variability in patients with type 2 diabetes mellitus and diabetic kidney disease has comple…
-
FDA approval · 2016-12-16FDA Approved: TRESIBA — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for TRESIBA (insulin degludec) submitted by Novo Nordisk.
-
CLINICAL_TRIALS trial_result · 2016-12-16Clinical Trial Update: A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India
A completed post-marketing surveillance study evaluating the safety and real-world use of liraglutide in adults with type 2 diabetes mellitu…
-
CLINICAL_TRIALS trial_result · 2016-12-16Clinical Trial Update: Making Ramadhan Fasting a Safer Experience With Technology Study [Phase 4]
A Phase 4 clinical trial completed that tested technology-assisted methods to make Ramadan fasting safer for people with Type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2016-12-15Clinical Trial Update: GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin [Phase 3]
Sanofi completed a Phase 3 trial evaluating lixisenatide (morning or evening dosing) added to metformin in adults with type 2 diabetes to as…
-
CLINICAL_TRIALS trial_result · 2016-12-15Clinical Trial Update: A Pilot Study of a Community Health Agent-led Diabetes Self-Management Program [NA]
A completed pilot trial evaluating a community health agent-led diabetes self-management program for adults with Type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2016-12-15Clinical Trial Update: Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus [Phase 4]
Phase 4 study evaluating the efficacy and safety of adding canagliflozin to insulin in adults with Type 2 Diabetes Mellitus; results were po…
-
FDA approval · 2016-12-14FDA Approved: PIOGLITAZONE AND METFORMIN HYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Pioglitazone and Metformin Hydrochloride fixed-dose combination from Macleods Pharmaceuticals Li…
-
CLINICAL_TRIALS trial_result · 2016-12-14Clinical Trial Update: GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea [Phase 3]
Phase 3 study evaluating lixisenatide added to sulfonylurea in type 2 diabetes to assess glycemic control and safety; results have been post…
-
CLINICAL_TRIALS trial_result · 2016-12-14Clinical Trial Update: GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin [Phase 3]
A Phase 3 trial evaluating lixisenatide added to metformin for glycemic control and safety in type 2 diabetes has completed, with results po…
-
CLINICAL_TRIALS research · 2016-12-13Clinical Trial Update: Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes
Observational study evaluating the safety, efficacy, and convenience of using NovoMix 30 FlexPen in individuals with type 2 diabetes; the st…
-
CLINICAL_TRIALS trial_result · 2016-12-13Clinical Trial Update: Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice
An observational study completed in routine clinical practice evaluating the efficacy, safety and convenience of Mixtard 30 NovoLet used alo…
-
FDA approval · 2016-12-12FDA Approved: ALOGLIPTIN — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for alogliptin, submitted by Padagis Israel Pharmaceuticals Ltd.
-
CLINICAL_TRIALS trial_result · 2016-12-12Clinical Trial Update: GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy [Phase 3]
Phase 3 trial evaluating lixisenatide as monotherapy for glycemic control and safety in adults with type 2 diabetes; results have been poste…
-
FDA approval · 2016-12-12FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for a fixed-dose combination of pioglitazone and glimepiride (Prasco Laboratories). The indicati…
-
FDA approval · 2016-12-12FDA Approved: ACTOPLUS MET — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ACTOPLUS MET (pioglitazone and metformin hydrochloride) from Takeda Pharmaceuticals America, Inc…
-
FDA approval · 2016-12-12FDA Approved: KAZANO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for KAZANO (alogliptin and metformin hydrochloride) filed by Takeda Pharmaceuticals America, Inc., i…